Cancer Research Technology
Log in Register
Menu

HEK293ΔNDUFS2 Cell Line

Invented by Abey Bandara
Invented at Virginia Tech

Info

Catalogue Number 156497
Antigen/Gene or Protein Targets NDUFS2
Parental Line HEK293
Synonyms HEK293ΔNDUFS2
Host Human
Disease Keywords Leighs; Mitochondrial disease; cardiomyopathy; encephalomyopathy
Model Knock-Out
Relevance The HEK293ΔNDUFS2 cell line expresses a CRISPR/Cas9 mutated NDUFS2, shown to significantly alter the function of complex I (CI) of the mitochondrial electron transport chain. This NDUFS2 mutant cell line displays disruptions to NDUFS2 that mimic isolated complex I deficiency and can be used as a powerful model of several types of mitochondrial disease.

Specific disruptions in the NDUFS2 gene have been reported to present clinically as the following disease conditions:
-Leigh syndrome
-Cardiomyopathy
-Encephalomyopathy
-Miscellaneous: basal ganglia and brainstem lesions, seizures, hypotonia, neonatal hypotonia, amaurosis, nystagmus, dysmorphic features, epilepsy and signs of brainstem involvement, and lactic acidosis.
Production Details The cell line is currently stored at Virginia Tech. By culturing approximately 1 million frozen cells in growth media, approximately 40 million cells can be harvested in a two weeks time.
Research Area Apoptosis and Programmed Cell Death, Cardiovascular, Drug Discovery & Development, Metabolism
Growth/Phenotype Keywords The mutant grows much slower than the parent cell line. The doubling time of the mutant is 3 times higher than that of the parent cell line.
Recommended Growing Conditions DMEM medium supplemented with 10% Fetal Bovine Serum and 1% Penicillin-Streptomycin at 37ºC temperature and 5-6% CO2.
Positive Control HEK293 parent line
Notes CRISPR edited HEK293 cells.

Cancer Research Technology Limited (trading research tools as Ximbio) has been granted a non-exclusive license to the CRISPR-Cas9 technology by ERS Genomics Ltd under the patent rights listed here.

This license from ERS Genomics Ltd allows Ximbio to develop and commercialise CRISPR-Cas9 modified cell lines for research use only. Ximbio can provide these modified CRISPR-Cas9 cell lines to companies under a label-use only license.

References

There are 1 reference entries for this reagent.

View All References

References: 1 entry

Bandara et al. 2021. Mitochondrion. 58:160-168. PMID: 33744462.


Add a reference

References: 1 entry

Bandara et al. 2021. Mitochondrion. 58:160-168. PMID: 33744462.


Add a reference

Inventor Information